| Name | Title | Contact Details |
|---|
Patient Pattern helps you take the next steps to identify, manage and communicate patient risk across care settings.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Parler company and culture information.
Triumph Tech is an AWS premier partner that provides cloud consulting services, specializing in cloud migrations, containers, serverless, data and analytics, ML & AI, and high performance compute.
Zeta empowers issuers to launch next-gen card programs with its cloud-native and fully API-enabled stack that includes processing, issuing, lending, core banking, fraud, loyalty, and many other capabilities. Zeta has 1400+ employees with over 70% in technology roles across locations in the US, UK, Middle East, and Asia. Globally, eight issuers and 30 fintechs have issued 15M+ cards on Zeta`s platform. Zeta has raised $280 million from Softbank Vision Fund 2, Mastercard, and other investors at a $1.5 billion valuation. Watch a short 7 minute video showcasing a fraction of the capabilities of Zeta Tachyon`s Credit processing stack here.